Life Biosciences Expands Team with the Appointment of Ming Yang, Ph.D., as SVP of Research and Development
Boston, MA, May 23, 2023 – Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation platforms to reverse diseases of aging and injury and ultimately restore health for patients, today announced the appointment of Ming Yang, Ph.D., as Senior Vice President of Research and Development. Dr. Yang will be responsible for overseeing the company’s research and development efforts and advancing its pipeline of cellular rejuvenation candidates.
“We are delighted to welcome Dr. Yang to the Life Bio team. He brings over 20 years of experience in translational biomedical research, with expertise in research and development from drug discovery to clinical development across a range of indications including ophthalmology – all of which will be critical in the next phase of our corporate development,” said Sharon Rosenzweig-Lipson, Ph.D., Chief Scientific Officer of Life Bio. “We look forward to working with him as we continue to develop innovative therapies for age-related diseases.”
Dr. Yang has a track record of building and leading multifunctional R&D teams and advancing early-stage research programs to clinical stage. Prior to joining Life Bio, he served as Senior Vice President of Research and Development at Graybug Vision, Inc., now CalciMedica Inc. (NASDAQ: CALC), where he led all R&D efforts to advance ophthalmic pipeline programs to clinical development and oversaw the operations of the company’s research center. Prior to Graybug, Dr. Yang conducted research to develop sustained-release protein therapeutics at Genentech, Inc.
“The work that Life Biosciences is doing has the potential to make a meaningful impact on the way we target and treat age-related diseases,” said Dr. Yang. “I look forward to working closely with the talented R&D team and the incredible leadership team to advance our pipeline of novel cellular rejuvenation therapies to restore cells to a more youthful state and bring new treatments to patients.”
Dr. Yang received his doctoral degree in biomedical engineering from Johns Hopkins School of Medicine and his bachelor of engineering in materials science and engineering from Tsinghua University. He has over 20 issued United States patents and has invented platform technologies that led to two FDA-approved drugs.
About Life Biosciences
Life Biosciences is a biotechnology company advancing innovative cellular rejuvenation platforms to reverse diseases of aging and injury and ultimately restore health for patients. The company is focusing on two platforms targeting key mechanisms underlying aging biology, epigenetic reprogramming and chaperone-mediated autophagy, to restore cells to a more youthful state. Therapies developed within these platforms have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com or follow us on Twitter and LinkedIn.
Media Contact
Justin Perry, Ph.D.
LifeSci Communications
jperry@lifescicomms.com
Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging- Related Diseases
Forge to provide cGMP manufacturing and development services for Life Biosciences’ novel adeno-associated virus (AAV) gene therapy platform for aging-related diseases, including in ophthalmic indications
BOSTON AND COLUMBUS, Ohio, May 8, 2023 – Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury and ultimately restore health for patients, and Forge Biologics (“Forge”), a genetic medicines manufacturing organization, today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications.
“Life Bio is an emerging leader in the development of novel therapies for aging-related diseases, and we are thrilled to serve as their cGMP manufacturing partner to help advance the manufacturing of AAV for their innovative cellular rejuvenation technology, which has the potential to benefit millions of aging patients worldwide,” said Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge.
Through this partnership, Forge will provide adeno-associated virus (AAV) process development, toxicology, cGMP manufacturing, and analytical services to Life Bio. The company will utilize Forge’s platform processes including its proprietary HEK293 suspension Ignition Cells™ and pEMBR™ adenovirus helper plasmid. All development and AAV manufacturing activities will occur at the Hearth, Forge’s 200,000 square foot gene therapy facility in Columbus, Ohio.
“We are delighted to be working with the Forge team, whose expertise in gene therapy manufacturing is unmatched,” said Jerry McLaughlin, Chief Executive Officer of Life Biosciences. “We believe we’re on the cusp of revolutionizing medicine with our cellular rejuvenation capabilities across a range of aging-related diseases, including ophthalmic disorders that involve retinal ganglion cell dysfunction. We are confident our partnership with Forge will have a tremendous impact on our ability to enhance the speed and quality with which we can manufacture our therapeutic candidates as we progress toward the first human clinical trials and continue to develop treatments to reverse diseases of aging by restoring cells to a more youthful state.”
About Life Biosciences
Life Biosciences is a biotechnology company advancing innovative cellular rejuvenation platforms to reverse diseases of aging and injury and ultimately restore health for patients. The company is focusing on two platforms targeting key mechanisms underlying aging biology, epigenetic reprogramming and chaperone-mediated autophagy, to restore cells to a more youthful state. Therapies developed within these platforms have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit lifebiosciences.com or follow us on Twitter and LinkedIn.
About Forge Biologics
Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life-changing gene therapies and help bring them from idea to reality. Forge’s 200,000 square foot facility utilizes 20 cGMP suites in Columbus, Ohio, the Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV manufacturing and hosts scalable, end-to-end manufacturing services. Offerings include process and analytical development, plasmid DNA manufacturing, viral vector manufacturing, final fill, as well as regulatory consulting support to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit www.forgebiologics.com.
Media Inquiries – Forge Biologics
Marina Corleto
Associate Director, Marketing and Communications
media@forgebiologics.com
Media Inquiries – Life Biosciences
Justin Perry, Ph.D.
Account Executive, LifeSci Communications
jperry@lifescicomms.com
Client Development – Forge Biologics
Taleen Barsoumian
Vice President, Client Development
CD@forgebiologics.com
Life Biosciences Presents Groundbreaking Data at ARVO Demonstrating Restoration of Visual Function in Nonhuman Primates
Data in a nonhuman primate model of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) demonstrates the ability to restore visual function after delivery of a novel gene therapy
BOSTON, April 23, 2023 — Life Biosciences, a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury and ultimately restore health for patients, today announced preclinical data in nonhuman primates (NHP) for its novel gene therapy candidate which uses a partial epigenetic reprogramming approach to restore visual function.
This approach has been shown to reverse aging, improve vision, and extend lifespan in mice, but whether epigenetic reprogramming would work in primates was not known. Today, researchers at Life Bio and academic researchers, including Dr. Bruce Ksander and Dr. David Sinclair, reported that Life Bio’s therapy significantly restored visual function in an NHP model of non-arteritic anterior ischemic optic neuropathy (NAION), a disorder similar to a stroke of the eye that is characterized by painless yet sudden loss of vision. The data, presented at the Association for Research in Vision and Ophthalmology (ARVO) 2023 conference in New Orleans, LA, represents an important step forward toward enabling human clinical trials to potentially treat a variety of ophthalmic disorders and other diseases of aging.
Life Bio’s lead platform reprograms the epigenome of older animals to resemble that of younger animals via expression of three Yamanaka factors, Oct4, Sox2, and Klf4, collectively known as OSK. The approach partially reprograms cells to resemble a more youthful state while retaining their original cellular identity. Previous data from Life Bio and academic researchers, which were also presented at ARVO 2023, have shown that treatment with OSK reverses retinal aging and restores vision in old mice in a mouse model of glaucoma. Now, with the data presented today at ARVO, the company has demonstrated restoration of visual function and increased nerve axon survival in an NHP model that mimics human NAION deficits in retinal ganglion cells. Key data highlights include the following:
- Laser-induced damage to the eyes of NHPs showed a reduction in the key ophthalmic measures that are typically seen in humans with NAION, including pattern electroretinogram (pERG) signals, optical coherence tomography (OCT), retinal nerve fiber layer (RNFL) thickness, and number of surviving optic nerve axons.
- NHPs received an intravitreal (in-eye) injection of doxycycline-inducible OSK viruses or vehicle one day after laser damage. Doxycycline was administered systemically until the end of the study.
- When eyes were treated with OSK after laser damage, OSK significantly restored pERG responses compared to controls, consistent with restoration of vision.
- OSK also significantly improved the number of healthy axon bundles compared to controls.
“NAION is the most common cause of acute optic neuropathy in people over 50, but currently has no effective treatment. The data we are presenting here show, for the very first time, that treatment with OSK can lead to significant recovery in affected visual function in an NHP model of NAION, the gold standard translational model. That potential unlocks new opportunities for cellular rejuvenation, not just in NAION but in other ophthalmic diseases that occur as a result of retinal ganglion cell dysfunction as we age,” said Bruce Ksander, PhD, Associate Professor of Ophthalmology and Co-Director of the Ocular Oncology Center of Excellence at Harvard Medical School, and lead presenter of the study at the ARVO conference.
Sharon Rosenzweig-Lipson, PhD, Chief Scientific Officer of Life Bio, added, “We are delighted to present this truly groundbreaking data, which further validate Life Bio’s innovative approach to cellular rejuvenation. This approach has implications far beyond NAION and even the vision field, and we are pleased to share data that support the continued development of our scientific platform to address diseases of aging and restore human health.”
Life Bio is advancing its cellular rejuvenation capabilities across a range of aging-related diseases, including additional ophthalmic and neurodegenerative indications. The data being presented at ARVO builds on previous findings from Dr. David Sinclair’s and Dr. Bruce Ksander’s labs at Harvard Medical School showing that OSK can reverse aging in mice.
Dr. Sinclair, Co-Founder of Life Bio, Member of the company’s Board of Directors, Professor in the Department of Genetics and Co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School, and coauthor on the study, said, “Demonstrating rejuvenation in nonhuman primates is a major step forward in advancing cellular rejuvenation as a way of treating both common and rare diseases in the eye and potentially other tissues. What we’ve learned in NHPs has important ramifications for research on reversing aging and is likely to be highly translational to humans. This data moves us an important step closer to the first clinical trials of how cellular rejuvenation technology could treat aging-related diseases.”
About Life Biosciences
Life Biosciences is a biotechnology company advancing innovative cellular rejuvenation platforms to reverse diseases of aging and injury and ultimately restore health for patients. The company is focusing on two platforms targeting key mechanisms underlying aging biology, epigenetic reprogramming and chaperone-mediated autophagy, to restore cells to a more youthful state. Therapies developed within these platforms have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit lifebiosciences.com or follow us on Twitter and LinkedIn.
About OSK
Life Bio’s lead platform, OSK, was invented in the lab of Professor David Sinclair, AO, PhD, Co-Founder of Life Bio, Member of the company’s Board of Directors, and Professor in the Department of Genetics and Co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School. The partial reprogramming technology was in-licensed by Life Bio from Harvard University. The technology was based on Dr. Sinclair’s Information Theory of Aging and works by reprogramming the epigenome of older animals to resemble that of younger animals via expression of three Yamanaka factors, Oct4, Sox2, and Klf4, collectively known as OSK. The approach partially reprograms cells to resemble a more youthful state while retaining their original cellular identity.
Media Contact
Gwendolyn Schanker
LifeSci Communications
gschanker@lifescicomms.com
Life Biosciences Appoints Sharon Rosenzweig-Lipson, PhD as Chief Scientific Officer
Dr. Rosenzweig-Lipson brings decades of experience in R&D strategy and clinical development as Life Biosciences advances therapeutics that target the biology of aging
BOSTON, February 13, 2023 – Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced the appointment of Sharon Rosenzweig-Lipson, PhD as Chief Scientific Officer. At Life Biosciences, she will be responsible for leading the company’s scientific research and development efforts built on the epigenetic reprogramming science of Dr. David Sinclair and the chaperone-mediated autophagy discoveries of Dr. Ana Maria Cuervo.
“Dr. Rosenzweig-Lipson brings great scientific and strategic leadership to Life Biosciences,” said Jerry McLaughlin, Chief Executive Officer at Life Biosciences. “Sharon has been serving as a consultant to Life since early 2021 and has helped to create strong processes to accelerate our drug discovery and development. Her impressive background and accomplishments in both preclinical and clinical development will continue to be invaluable to us as we progress our therapies toward the clinic. It is a pleasure to officially welcome her to the team.”
“I am thrilled to be joining Life Biosciences to revolutionize the treatment of a wide-range of age-related disorders,” said Dr. Rosenzweig-Lipson. “I look forward to collaborating with the strong mission-driven team at Life Biosciences and its outstanding scientific collaborators.”
Dr. Rosenzweig-Lipson holds significant expertise in screening strategies, in vivo models, translation, and clinical development strategy with more than three decades of experience developing compounds for psychiatric and neurologic indications in the pharmaceutical industry and in biotech. Her career in big pharma includes American Cyanamid, American Home Products, Wyeth, and Pfizer. Most recently, as head of R&D, Dr. Rosenzweig-Lipson led the clinical development of AgeneBio’s lead asset through Phase 2B trials as well as the company’s preclinical development programs. Dr. Rosenzweig-Lipson earned her BA in the biological basis of behavior from the University of Pennsylvania and her PhD in behavioral neuroscience from Harvard University.
About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to discovering and developing novel therapies to improve the lives of people as they age. The company is focusing on two platforms targeting key mechanisms underlying aging biology: epigenetic reprogramming to restore cellular function to a more youthful state and chaperone-mediated autophagy to reverse the age-related decline in the body’s ability to recycle unwanted proteins. Therapies developed within these platforms have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.
Media
media@lifebiosciences.com
Life Biosciences CEO Jerry McLaughlin to Speak at Roadmap to Healthy Longevity International Summit
BOSTON, February 9, 2023 — Life Biosciences, a pioneering biotech company developing therapeutics that target the biology of aging, today announced that Jerry McLaughlin, Chief Executive Officer, will speak at the Roadmap to Healthy Longevity: Enabling Healthier, Longer Lives in the GCC conference February 19, 2023, in Riyadh, Saudi Arabia. McLaughlin will participate on a panel entitled “Meet the Healthy Longevity Innovators.”
“Our scientific team at Life Biosciences is at the cutting edge of developing novel therapies based on exciting advances in age-related science,” said McLaughlin. “I’m proud to speak at this important international conference to discuss developments in the bourgeoning healthspan space that are rooted in innovative science as well as to share more about Life’s scientific progress to date and its robust pipeline.”
About the Conference
Jointly organized by the US National Academy of Medicine (NAM), Hevolution Foundation, and the King Abdullah International Medical Research Center (KAIMRC), the event will gather leaders from across the longevity ecosystem to discuss the state of longevity and healthy lifespan in the Gulf Region and an envisioned world with healthy longevity by 2050.
About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to discovering and developing novel therapies to improve the lives of people as they age. The company is focusing on two platforms targeting key mechanisms underlying aging biology: epigenetic reprogramming to restore cellular function to a more youthful state and chaperone-mediated autophagy to reverse the age-related decline in the body’s ability to recycle unwanted proteins. Therapies developed within these platforms have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.
Life Biosciences to Present at Longevity Leaders World Congress 2022
BOSTON, April 14, 2022 — Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced that Jerry McLaughlin, Chief Executive Officer, will speak at the fourth annual Longevity Leaders World Congress being held on April 26-27, 2022, in London, UK.
Mr. McLaughlin will deliver a presentation on April 26 at 11:10 BST titled, “Targeting Mechanisms Underlying the Biology of Aging to Treat and Reverse Disease.”
“Life Biosciences is truly at the forefront of developing novel therapies based on exciting advances in age-related science,” says Mr. McLaughlin. “I’m delighted to have the opportunity to share more about our work and progress here at Life Biosciences and discuss ways to work with pioneers in the field to move our industry forward.”
The Longevity Leaders World Congress, hosted by LSX, brings the world’s most prominent regenerative medicine and longevity scientists together, presenting the new research, responsible drug development, novel therapies, and commercialization to target age-related diseases. Those interested in attending the conference may register here.
About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to discovering and developing novel therapies to improve the lives of people as they age. The company is focusing on three platforms targeting key mechanisms underlying aging biology: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Therapies developed within each platform have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.
Media
media@lifebiosciences.com
Investor Relations
Bill Sullivan
IR@lifebiosciences.com
Life Biosciences, Leading Developer of Therapeutics for Aging-Related Diseases, Completes $82 Million Series C Financing Round
Announces Bill Sullivan as Chief Financial Officer
BOSTON, Jan. 5, 2022 — Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced the completion of a Series C financing of $82 million led by Alpha Wave Ventures. Senior management and founders invested in the Series C financing alongside longevity-oriented funds, seasoned investors, and experienced biotechnology scientists/entrepreneurs. Since its founding, Life Biosciences has raised over $158 million.
“Our three platforms are based on seminal research demonstrating that aging biology can be modified therapeutically. The Series C funding enables us to accelerate development of our innovative therapies for multiple aging-related conditions, and we expect to initiate first-in-human studies for our first drug candidate possibly as early as the end of 2022,” said Chief Executive Officer Jerry McLaughlin. “We appreciate the support of both our new and existing investors as we advance the company to its next stage of development. Life Biosciences’ experienced management team is committed to bringing potentially pioneering science to the service of humanity.”
Proceeds from the Series C financing will be used to accelerate research and development activities in the company’s three platforms that target fundamental biological mechanisms contributing to aging. The mitochondrial uncoupling platform is developing oral small molecules that are designed to increase metabolic rate and decrease fat accumulation in models of obesity and NASH. The chaperone-mediated autophagy (CMA) platform is developing oral small molecules that are designed to activate CMA and thereby remove unwanted proteins that accumulate during aging and contribute to multiple aging-related diseases including neurodegenerative diseases. The epigenetic reprogramming platform is developing therapies that are designed to induce the expression of three Yamanaka factors to reprogram the epigenome of cells to a younger state and thereby restore cellular function across a wide range of diseases such as glaucoma.
Commenting on the investment, Alpha Wave Global Chairman Rick Gerson added, “We are impressed by the groundbreaking science that has been published in leading and recently peer-reviewed journals like Nature and Cell by the company’s co-founder and director David Sinclair and other founder scientists such as Dr. Ana Maria Cuervo. Their foundational science could revolutionize how we develop therapies for aging-related conditions. We are excited to invest in this emerging field and believe that Life Biosciences’ experienced management team and exceptional science has the potential to unlock a new wave of therapies across their multiple platforms.”
In addition, Life Biosciences announces the appointment of Bill Sullivan as Chief Financial Officer. Bill brings more than 25 years of experience in corporate finance, strategic transactions, fundraising, and investor relations. He served as Chief Financial Officer and Treasurer at Applied Genetic Technologies Corporation, a publicly traded gene therapy company, where he led multiple financings and core business and finance functions. Prior to AGTC, he worked at Merrimack Pharmaceuticals, Inc. for ten years and held a variety of important leadership positions including Chief Financial Officer.
“It’s an honor to join the Life Biosciences team as the company pursues tremendous growth opportunities where aging biology has a clear link to disease pathogenesis,” said Mr. Sullivan. “I’m energized by both the people and strong science at the company and look forward to working together with the management team to drive the next phase of growth.”
“I couldn’t be more delighted by the progress made by the Life Biosciences’ team under Jerry’s leadership to sharpen its focus on developing therapeutics on a platform-oriented approach. In my opinion, Life Biosciences is on the cusp of revolutionizing medicine for aging-related diseases globally,” said Executive Chairman Dr. Mehmood Khan.
About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to discovering and developing novel therapies to improve the lives of people as they age. The company is focusing on three platforms targeting key mechanisms underlying aging biology: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Therapies developed within each platform have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.
About Alpha Wave Global
Alpha Wave is a global investment company with offices in New York, Miami, London, Abu Dhabi, Tel Aviv, and Bangalore. Its flagship global venture and growth fund, Alpha Wave Ventures, aims to invest in best-in-class venture and growth-stage companies and endeavors to be helpful long-term partners to the founders and management teams. Alpha Wave manages a variety of investment partnerships that cover a number of asset classes, themes, and geographies. For more information, please visit www.alphawaveglobal.com.
Media Contact
Maggie Farrand
media@lifebiosciences.com
Life Biosciences Receives Translational Research Funding from Alzheimer’s Drug Discovery Foundation
BOSTON, Sept. 28, 2021 — Life Biosciences, a pioneering life sciences company developing therapeutics that target the biology of aging, today announced translational research funding from the Alzheimer’s Drug Discovery Foundation (ADDF) to support the development of chaperone-mediated autophagy (CMA) activators for the treatment of Alzheimer’s disease and other neurodegenerative diseases.
Chaperone-mediated autophagy removes unwanted soluble proteins from cells. CMA activity declines with age due in part to decreased expression of LAMP2A, a key protein regulating CMA activity. The age-related decline of CMA leads to an accumulation of insoluble proteins that disrupt cellular function in age-related diseases such as Alzheimer’s disease.
In groundbreaking work published in the peer-reviewed journal Cell in April 2021, Professor at the Albert Einstein College of Medicine and Life Biosciences founder scientist Ana Maria Cuervo, MD, PhD demonstrated the benefit of the CMA-activator platform in two mouse models of Alzheimer’s disease. In both models, oral doses of CMA-activator compounds led to improvements in memory, depression, and anxiety. Life Biosciences has an exclusive license from Albert Einstein College of Medicine for this underlying technology and will continue this research by evaluating CMA-activator compounds for key early attributes needed in Alzheimer’s disease drug development.
“We are pleased to have received this translational research funding from the ADDF, which further validates the potential of our CMA platform to treat devastating diseases such as Alzheimer’s,” said Jerry McLaughlin, Chief Executive Officer of Life Biosciences. “Our preclinical work to date has demonstrated that CMA activation may be a viable therapeutic strategy in halting the progression of age-related neurodegenerative disorders and ultimately increase healthy human lifespan. We look forward to advancing this platform towards the clinic with the support of the ADDF.”
“Life Biosciences’ innovative pathway holds exciting promise for the potential treatment and prevention of Alzheimer’s disease,” said Howard Fillit, MD, Founding Executive Director and Chief Science Officer of the ADDF. “After substantial scientific review, we believe that CMA could offer a unique approach to Alzheimer’s disease, and we look forward to partnering with Life Biosciences as it advances its important research towards the clinic.”
About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to developing novel therapies to extend healthy human lifespan. The Company is focusing on three platforms targeting key mechanisms underlying aging biology: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Therapies developed within each platform have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.
About the Alzheimer’s Drug Discovery Foundation
Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer’s disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer’s and related dementias, employing a venture philanthropy model to support research in academia and the biotech industry. Through the generosity of its donors, the ADDF has awarded more than $168 million to fund over 650 Alzheimer’s drug discovery and biomarker programs and clinical trials in 19 countries. To learn more, please visit: http://www.alzdiscovery.org/.
Media Contact
Maggie Farrand
media@lifebiosciences.com
Life Biosciences Appoints Seasoned Biopharma Executive Jerry McLaughlin as CEO
Dr. Mehmood Khan to remain Executive Chairman
BOSTON, July 1, 2021 — Life Biosciences, a pioneering life sciences company targeting the biology of aging, today announced that the Company’s Board of Directors has appointed Jerry McLaughlin as Chief Executive Officer and a member of the Board. Dr. Mehmood Khan will serve as Executive Chairman of the Board.
“I welcome Jerry to the Life Biosciences team at this exciting time for the company,” said Life Biosciences co-founder and Board member David Sinclair, PhD, AO. “Jerry’s extensive experience leading both public and private companies through clinical development and financing will be an invaluable asset as we advance our multiple leading programs. I would also like to thank Dr. Khan for leading Life Biosciences and achieving important milestones over the past few years, including progressing our three platforms toward the clinic. Mehmood’s continued guidance as Executive Chairman, along with Jerry’s stewardship as CEO, will position Life Biosciences for lasting success.”
“It has been a privilege to serve as Life Biosciences’ CEO, and I am proud of the work we have accomplished together,” said Dr. Khan. “With Jerry’s strong track record of operational excellence, innovation, and delivering results, I am confident he is the ideal person to lead Life Biosciences through its next pivotal phase. I look forward to working with him as Executive Chairman.”
Mr. McLaughlin has over 30 years of experience in the biopharmaceutical industry and has been involved in the discovery, clinical development, and global commercialization of more than a dozen FDA-approved drugs with multiple successful exits. Most recently, he was President and CEO for Neos Therapeutics, Inc., a commercial stage pharmaceutical company. Before that, Mr. McLaughlin served as President and CEO of AgeneBio, Inc., a clinical-stage private biopharma company developing therapies for neurological and psychiatric diseases. Earlier, he held the role of Senior Vice President & Chief Commercial Officer at NuPathe Inc., acquired by Teva Pharmaceuticals in 2014. Mr. McLaughlin began his career at Merck and was extensively involved in multiple blockbuster product launches. He holds a BA in economics from Dickinson College and an MBA from the Villanova School of Business.
“I am thrilled to join Life Biosciences as the company works to advance its first programs toward the clinic,” said Mr. McLaughlin. “Having led companies for over a decade that address neurological and psychological conditions and deficits, I am well versed with the negative impacts of aging on the brain and body. Life Biosciences’ groundbreaking work to address and treat the underlying biology of aging has the potential to lead the next generation of therapies for a growing population that faces increasing challenges from diseases that correlate tightly with growing older.”
Dr. Khan will become CEO at a newly founded global non-profit organization focused on funding research on therapies that address aging biology and extend human healthspan. Dr. Khan’s new role is complementary to Life Biosciences’ research and development work, and he will continue to support the Company as Executive Chairman. Additional details relating to Dr. Khan’s new role will be announced later this year.
About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to developing novel therapies to extend healthy human lifespan. The Company is focusing on three platforms targeting key mechanisms underlying aging biology: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Therapies developed within each platform have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.
Media Contact
Maggie Farrand
media@lifebiosciences.com
Life Biosciences Announces Publication in Cell Demonstrating Therapeutic Benefit of Chaperone-Mediated Autophagy Activators in Alzheimer’s Disease Models
BOSTON, April 22, 2021 — Life Biosciences, a pioneering life sciences company targeting the biology of aging, today announced the publication of preclinical research demonstrating clinical benefit of its chaperone-mediated autophagy activator platform in mice models of Alzheimer’s disease. The article, titled “Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome“ by Bourdenx et al., was published online in the peer-reviewed journal Cell on April 22, 2021.
Chaperone-mediated autophagy (CMA) controls the levels of soluble proteins in cells. It has been proposed that the age-related decline of CMA leads to an increased concentration of insoluble proteins that may play a role in the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease. This study demonstrated that the upregulation of CMA with one of Life Biosciences’ tool oral compounds significantly improved neurologic function and decreased the accumulation of insoluble protein aggregates in two different mouse models of Alzheimer’s disease, even after the onset of neurologic dysfunction.
“The publication of this preclinical study validates our CMA platform and demonstrates that an age-related decline in CMA activity may contribute to the pathogenesis of Alzheimer’s disease,” said Joan Mannick, MD, Head of Research and Development at Life Biosciences. “As we look ahead, we anticipate advancing our platform of CMA activating candidates towards the clinic for the potential treatment of aging-related diseases including neurodegenerative diseases.”
Ana Maria Cuervo, MD, PhD, a Life Biosciences founder scientist and Professor and Co-Director of the Institute for Aging Research at the Albert Einstein College of Medicine, commented, “The results of this study identify a direct contribution of CMA to the maintenance of the neuronal proteome in vivo in physiological and pathological conditions. Additionally, this paper provides evidence of the potential value of CMA activation as a therapeutic strategy for age-related neurodegenerative disorders. We look forward to progressing the clinical development of our compounds that activate CMA and believe that this new approach has the potential to prevent the buildup of insoluble proteins that underlie neurologic dysfunction.”
Life Biosciences has in-licensed the intellectual property related to targeting of CMA from Albert Einstein College of Medicine.
About Life Biosciences
Life Biosciences is a private biotechnology company dedicated to developing novel therapies to extend healthy human lifespan. The Company is focusing on three platforms targeting key mechanisms underlying aging biology: mitochondrial uncoupling, chaperone-mediated autophagy, and epigenetic reprogramming. Therapies developed within each platform have the potential to prevent, treat, and/or reverse multiple aging-related diseases. For more information, please visit www.lifebiosciences.com.
Media Contact
Maggie Farrand
media@lifebiosciences.com
Investor Relations Contact
Stern Investor Relations
Alexander Lobo
alex.lobo@sternir.com